As part of our Crystal Ball series, we asked BBK Worldwide President Matt Kibby to comment on the clinical research landscape and to share his predictions for 2021.
Matt Kibby, Principal, President
Is there a particular trend that you expect to have a significant impact on the industry in the coming year?
With COVID-19 dominating the headlines for much of 2020, one might expect that a key development for clinical R&D in 2021 will be the continued integration and expansion of services that support the hybridization / decentralization of clinical trials. Keeping trial participants – who tend to be older and at greater risk for complications from COVID-19 – away from clinical trial sites not only reduces the risk of SARS-COV-2 infection, but also offers the possibility of enrichment of the clinical trial experience; reduces the overall visit and expense burden for patients; and, moreover, reduces the trial burden on clinical trial site healthcare professionals.